AAV2 Gene Therapy Readministration in Three Adults with Congenital Blindness
Jean Bennett(Penn Presbyterian Medical Center), Albert M. Maguire(Children's Hospital of Philadelphia), Kenneth S. Shindler(Penn Presbyterian Medical Center), Jennifer Wellman(Children's Hospital of Philadelphia), Jeannette Bennicelli(Penn Presbyterian Medical Center), Sarah McCague(Children's Hospital of Philadelphia), Eric A. Pierce(Massachusetts Eye and Ear Infirmary), Federico Mingozzi(Inserm), Laura Cyckowski(Children's Hospital of Philadelphia), Junwei Sun(Singapore Management University), Katherine A. High(Spark Therapeutics (United States)), Manzar Ashtari(California University of Pennsylvania), J. Fraser Wright(Oxford BioMedica (United Kingdom)), Xiaosong Zhu(Linyi People's Hospital), Gui‐Shuang Ying(Philadelphia College of Osteopathic Medicine), Yifeng Chen(Children's Hospital of Philadelphia), Daniel C. Chung(Penn Presbyterian Medical Center), Alberto Auricchio(Federico II University Hospital), Kathleen Marshall(Children's Hospital of Philadelphia), Francesca Simonelli(University of Naples Federico II)
Cited by 390
Related Papers
Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration
|Ophthalmology|2012|1.7k
Gene therapy comes of age
|Science|2018|1.4k
Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins.
|Proceedings of the National Academy of Sciences|1995|1.3k
Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial
|The Lancet|2009|857
Diabetic Retinopathy Preferred Practice Pattern®
|Ophthalmology|2019|703